Idexx Laboratories, Inc (NASDAQ: IDXX) on Tuesday, plunged -0.29% from the previous trading day, before settling in for the closing price of $475.07. Within the past 52 weeks, IDXX’s price has moved between $356.14 and $548.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 10.23% over the last five years. The company achieved an average annual earnings per share of 13.72%. With a float of $79.59 million, this company’s outstanding shares have now reached $80.74 million.
The firm has a total of 11000 workers. Let’s measure their productivity. In terms of profitability, gross margin is 61.32%, operating margin of 29.19%, and the pretax margin is 28.6%.
Idexx Laboratories, Inc (IDXX) Insider Activity
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Idexx Laboratories, Inc is 1.03%, while institutional ownership is 92.83%. The most recent insider transaction that took place on May 02 ’25, was worth 1,329,167. Before that another transaction happened on Feb 10 ’25, when Company’s Executive Vice President sold 9,986 for $462.53, making the entire transaction worth $4,618,862. This insider now owns 8,176 shares in total.
Idexx Laboratories, Inc (IDXX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 13.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.15% during the next five years compared to 16.90% growth over the previous five years of trading.
Idexx Laboratories, Inc (NASDAQ: IDXX) Trading Performance Indicators
Idexx Laboratories, Inc (IDXX) is currently performing well based on its current performance indicators. A quick ratio of 0.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.69. Likewise, its price to free cash flow for the trailing twelve months is 44.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.82, a number that is poised to hit 3.27 in the next quarter and is forecasted to reach 13.62 in one year’s time.
Technical Analysis of Idexx Laboratories, Inc (IDXX)
Analysing the last 5-days average volume posted by the [Idexx Laboratories, Inc, IDXX], we can find that recorded value of 1.19 million was better than the volume posted last year of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 83.97%. Additionally, its Average True Range was 16.66.
During the past 100 days, Idexx Laboratories, Inc’s (IDXX) raw stochastic average was set at 92.02%, which indicates a significant increase from 88.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.74% in the past 14 days, which was higher than the 38.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $424.04, while its 200-day Moving Average is $447.17. Now, the first resistance to watch is $480.62. This is followed by the second major resistance level at $487.53. The third major resistance level sits at $495.34. If the price goes on to break the first support level at $465.90, it is likely to go to the next support level at $458.09. Should the price break the second support level, the third support level stands at $451.18.
Idexx Laboratories, Inc (NASDAQ: IDXX) Key Stats
Market capitalization of the company is 38.10 billion based on 80,422K outstanding shares. Right now, sales total 3,898 M and income totals 887,870 K. The company made 998,430 K in profit during its latest quarter, and 242,680 K in sales during its previous quarter.
